GlySure, Ltd., has developed a continuous intravascular glucose monitoring system to meet the $5B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the Hospital Intensive Care Unit (ICU). Hospital TGC has been shown in prospective outcomes trials to produce significant improvement in patient outcomes including 46% reduction in incidence of sepsis, 41% reduction in renal failure, and 34% reduction in mortality. The challenge for hospitals is that using insulin to tightly control blood glucose increases the risk of hypoglycemia which has itself been associated with increased mortality. To safely implement TGC requires near hourly sampling of blood glucose levels to ensure the patient stays in the target range - a time and resource requirement that most hospitals cannot meet. In a recent editorial in Critical Care, James Krinsley summed up the need for hospital CGM as follows, "Successful management of all three domains of glycemic control will require the use of continuous or nearly continuous technologies. Fortunately, this era is about to begin." GlySure has demonstrated through clinical testing on over 200 ICU patients, highly accurate sensors and systems. The company has recently received ISO 13485 certification and completed enrollment in a CE regulatory trial on cardiac surgery patients showing accurate monitoring throughout the length of stay in ICU.
Show more
Abingdon, GB
Size (employees)
13 (est)
GlySure was founded in 2006 and is headquartered in Abingdon, GB
Report incorrect company information

GlySure Office Locations

GlySure has an office in Abingdon
Abingdon, GB (HQ)
Units 4-6 The Quadrant Abingdon Science Park Abingdon Oxfordshire
Show all (1)
Report incorrect company information

GlySure Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$24.4 m

Latest funding size

$13.60 m

Time since last funding

6 years ago


GlySure's latest funding round in November 2012 was reported to be $13.6 m. In total, GlySure has raised $24.4 m
Show all financial metrics

GlySure Financials

Cash (31-Mar-2017)

39.5 k
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017


156 k299.7 k628 k91.8 k3.8 m1.8 m462.1 k465.2 k16.4 k39.5 k

Accounts Receivable

98.7 k159.4 k263 k292.4 k388.3 k567.4 k636.6 k998.8 k1.1 m

Current Assets

345.1 k459.1 k891 k384.1 k4.2 m2.4 m1.1 m1.5 m1.1 m935.6 k


83.6 k68.2 k308.3 k252.6 k348.5 k448.4 k379.4 k378.9 k223.1 k118.8 k
Y, 2017

Financial Leverage

-0.1 x
Show all financial metrics
Report incorrect company information

GlySure Online and Social Media Presence

Embed Graph
Report incorrect company information